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Abstract
Introduction Intertransverse posterolateral fusion along
with instrumentation is a common technique used for spinal
fusion. Iliac crest bone graft (ICBG) oVers good fusion suc-
cess rates with a low risk for disease transmission but is,
however, linked with certain morbidity. In an eVort to elim-
inate or reduce the amount of iliac graft needed, bone sub-
stitutes including demineralized bone matrix (DBM) have
been developed. This study evaluates a novel DBM (Accell
Connexus®) used in one or two-level instrumented postero-
lateral lumbar fusion.
Materials and methods A total of 59 consecutive patients
were studied as two groups. Group 1 consisted of 33
patients having Accell Connexus® used to augment either
ICBG or local decompression material. Group 2 consisted
of 26 consecutive patients, operated prior to the introduc-
tion of this novel DBM, having either ICBG alone or local
decompression material. Fusion was assessed by two inde-
pendent observers, blinded to graft material, using stan-
dardized criteria found in the literature. All adverse events
were recorded prospectively.
Results The results show no statistically signiWcant diVer-
ences between the two groups in fusion rates, complica-
tions, surgery duration, ODI, or pain on VAS. Logistical
regression showed no relation between fusion and age,
smoking status or comorbidities. Furthermore, no adverse
events related to the use of the novel DBM were observed.
Conclusion The results from this study demonstrate that
the novel DBM presented performs equally as well as that
of autologous bone, be it either ICBG or a local decompres-
sion material, and can therefore be used as a graft extender.
Keywords Demineralized bone matrix (DBM) · 
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Introduction
Spinal fusion is one of the most common procedures per-
formed in spinal surgery, with more than 200,000 annual
cases performed in the United States alone [2]. Intertrans-
verse posterolateral fusion (PLF) along with instrumenta-
tion is one of the common techniques used in spinal fusion
and the osseous repair procedure where the most bone graft
material is used. From the many bone-grafting options
available, iliac crest bone graft (ICBG) remains the most
popular. ICBG oVers good success rates and low risk for
disease transmission [10]. Harvesting of ICBG is neverthe-
less linked with certain morbidity. Reported complications
include hematoma, false aneurysm, nerve and arterial inju-
ries [5,13,17], gait disturbances, fractures of the iliac wing
[7,11,15,16], visceral and ureteral injuries [8,14], peritoneal
perforation, infections [13], sacroiliac instability, and pain
[13]. In particular, residual pain has been reported to occur
in as much as 31% of the cases [9].
In an eVort to reduce the amount of iliac graft needed,
several bone substitutes have been developed. Demineral-
ized bone matrix (DBM) is one of these because it has
been shown that properly demineralized cortical bone
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and growth factors [22]. Although initial DBMs contained
glycerol as a carrier for the DBM particles, this substance
has been found to be detrimental for host cells and nephro-
toxic at high doses [3, 23] and can migrate within the site
or upon irrigation due to the water solubility of the carrier.
Newer DBMs are therefore being developed with
improved carrier composition and increased matrix induc-
tion concentration. Studies based on Wrst generation
DBMs are available in the literature [4, 19]. To our knowl-
edge however, there are no clinical studies available on the
safety and eYcacy of these newer generation DBMs for
spinal fusion.
The objective of this pilot study was to evaluate the clin-
ical and radiological performance of a novel DBM (Accell
Connexus®) composed of a DBM-based carrier with a
reverse phase copolymer additive (IsoTis OrthoBiologics
Inc., Irvine, CA, USA) used as a graft extender in one or
two-level instrumented posterolateral lumbar fusion.
Materials and methods
A total of 59 consecutive patients (22 males and 37
females) were included in the study. All the patients under-
went one- or two-level instrumented intertransverse fusion.
Diagnosis included lumbar spinal stenosis with spondylo-
listhesis (n = 37), degenerative disc disease (n = 11), lum-
bar fractures (n = 2), and isthmic spondylolisthesis (n = 9);
40 patients had one-level fusion and the remaining 19 had
two-level fusion. The patients were organized in two
groups. Group 1 comprised 33 consecutively operated
patients (average age of 64.6 years) in whom 2.5–10 cm3 of
Accell Connexus® putty combined with an autologous bone
marrow aspirate from the iliac crest was used to augment
either ICBG, or a local decompression material, in a stan-
dardized ratio as per the manufacturer’s recommendations
(1:1 with 5 cm3 of bone marrow). This ratio is aimed at
obtaining adequate containment of all the autograft parti-
cles while maximizing the inductive potential provided as a
stimulus to the native osteogenic autograft and is consid-
ered as the right balance for this purpose in the absence of
studies on the subject. The addition of the reverse phase
copolymer to the DBM-based substance allows for com-
posite graft containment and the ability to irrigate once
placed. The control group (Group 2) consisted of 26 con-
secutive patients (average age of 58.3 years) operated on
prior to the introduction of Accell Connexus® in our institu-
tion. ICBG alone, or local decompression material, was
used for these patients. In both the groups the grafting
material was placed posterolateraly over the transverse
processes or lateral mass of the sacrum following decortica-
tion. All the patients received rigid titanium 6 mm
polyaxial pedicle screws originating from the same manu-
facturer (Expedium, DePuy Spine Inc., Raynham, MA,
USA). Age, distribution of the type of diagnosis, and the
number of two-level fusions performed, were similar for
both the groups. All the patients were treated by the same
senior surgeon (CS) in one institution. Prophylactic antibi-
otics and low molecular weight heparin were used by all the
patients. Non-steroidal anti-inXammatory drugs (NSAIDs)
were proscribed during the Wrst 3 months for both the
patient groups. A soft orthosis was used in all patients for
the Wrst 6 weeks following surgery. The proportion of
smokers was 27 and 34% for groups 1 and 2, respectively.
Patients were followed up clinically and radiologically, at
6 weeks, and at 3, 6 and 12 months post surgery. No patient
from either group was lost to follow-up. Ethical committee
approval was obtained by the institutional review board and
all patients gave their informed consent.
Radiographically, the Christensen et al. fusion criteria
for union [6] were applied to study plain X-rays taken at
12 months. According to this classiWcation, “fusion” indi-
cates qualitative fusion at all intended levels (Figs. 1, 2).
Suboptimal quality or a fusion mass hidden by instrumenta-
tion is to be counted as “non-fusion”. The clinical outcome
measures employed were the Oswestry disability index
Fig. 1 A radiograph showing an anteroposterior (AP) view of a two-
level fusion following decompression taken immediately post-surgery.
Grafting consisted of decompression material and DBM. The entire
graft mass is not readily observed as the DBM is not radiopaque123
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(VAS), given preoperatively and one year post-surgery.
Two independent observers, blinded to the type of graft
material, assessed the Wlms for the presence of bridging
bone between the transverse processes using a consensus
interpretation. All adverse events and complications were
recorded prospectively for both groups. Statistical analyses
were performed utilizing Fisher’s exact two-tailed test,
Student’s unpaired t test and a logistic regression.
Results
No signiWcant diVerence (P = 0.86) was found between
operating times for group 1 (average = 241 min) and group
2 (average = 244 min). No deep infections occurred in
either group. Furthermore, no adverse event related to the
use of DBM was noted. In particular, no intraoperative
hypotension or allergic reaction was registered. One patient
from each group suVered a pulmonary embolus recovering
uneventfully following appropriate treatment. There were
two dural tears in group 1 and one in group 2, both treated
with primary repair, and resulting in no long-term conse-
quences.
Fusion was found in 23 out of the 33 (69.7%) patients
from group 1, and 20 out of the 26 (76.9%) patients from
group 2. This diVerence was not statistically signiWcant
(Table 1). In addition, subgroup analyses showed no sig-
niWcant diVerence (P = 0.77) in fusion rates between
patients receiving decompression material alone or those
augmented with ICBG. Furthermore, there was no statisti-
cal diVerence in the preoperative VAS and ODI or in their
improvement reported at one year post-surgery between the
two groups. Average values and levels of signiWcance can
be found in Table 1. No implant failure was observed in
either group.
Results from a logistic regression analysis showed no
relation between the occurrence of radiological fusion and
age, smoking status, comorbidities, length of surgery, vol-
ume of DBM, or pain (VAS) and function (ODI) reported
at 1 year.
Discussion
This study focuses on the safety and eYcacy of a new
DBM-based osteoinductive bone graft material used as a
Fig. 2 A follow-up AP radiograph to that shown in Fig. 1 taken 1 year
post-surgery demonstrating “fusion” according to the Christensen
et al. criteria for all intended fusion levels. The fusion mass is particu-
larly well visible on the patient’s right side (see arrows), demonstrating
new bone formation and mineralization
Table 1 Summary of signiW-




Operating time (min) 241 244 P = 0.86 (t-test)
Fusion rates (%) 69.7 76.9 P = 0.57 (Fisher’s)
Average ODI (1 year post-operative) 24.1 28.8 P = 0.38 (t-test)
Average ODI improvement 
(1 year post-operative–pre-operative) 
32.7 30.5 P = 0.70 (t-test)
Average VAS (1 year post-operative) 3.4 4.2 P = 0.30 (t-test)
Average VAS improvement 
(1 year post-operative–pre-operative)
4.5 4.9 P = 0.67 (t-test)123
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mented lumbar fusion. Several studies, reviewed and sum-
marized by Lee at al. [18], have been carried out using
various animal models and DBM preparations to demon-
strate diVerences in fusion rates based on several factors
including the DBM formulation, and the animal model
used. Fewer studies, however, can be currently found in the
literature covering the use of DBM in a human clinical pop-
ulation. Studies have evaluated previous generation DBMs
(Grafton) for posterolateral lumbar fusion [4,12,20,21].
From these studies, one showed lower fusion rates using
coralline hydroxyapatite with the addition of DBM [21],
and the others demonstrated the utility of DBMs as graft
extenders but not as fusion enhancers [4,12,20].
The fusion rates in the present study are lower than those
commonly cited and tacitly accepted (approaching 90%)
for instrumented posterolateral fusion using autologous
ICBG. Camissa et al. [4], in their study on the use of Graf-
ton, also noted relatively lower rates (65%) which they
ascribed to a very diYcult to manage patient population,
very strict radiographic criteria and the need to evaluate the
graft visible lateral to the instrumentation. The latter in our
opinion, may have contributed to some extent in our study
as well, with the other two reasons being more diYcult to
quantify. Indeed evaluating graft visibility lateral to the
instrumentation may underestimate the true fusion rates. It
could be that if more autologous graft volume is used (e.g.,
from minced local bone), and if rods are more medially
placed, the visibility of the fusion mass would be enhanced
without necessarily increasing the fusion rate. It is interest-
ing to note that in our department the revision rate for
pseudarthrosis is less than 1% for patients treated in exactly
the same manner prior to the beginning of the present
study, albeit without the use of DBM.
The use of plain radiographs presents a limitation in
assessing fusion when compared to the suggested improved
accuracy observed from the use of computed tomography
(CT) images. Using CT images however, subjects patients
to increased amounts of radiation which we found an
unnecessary risk considering the simplicity and good inter-
and intra-observer agreement [6] reported for the radiologi-
cal criteria chosen.
An added caveat to the results presented, is the shorter
than 2 years follow-up period as has been previously sug-
gested [1]. We did nevertheless succeed in obtaining a
100% 1 year follow up chieXy through the excellent com-
pliance of our patient population. In addition, this study
was not randomized but consisted of a consecutive series of
patients before and after the availability of the aforemen-
tioned DBM in our institution. The study beneWts from
being performed at a single institution by the same operat-
ing surgeon eliminating possible technical diVerences such
as graft harvesting and preparation of the graft bed.
In summary, the results of this study demonstrate the
role of this novel DBM as a safe and eVective graft
extender in one or two level posterolateral instrumented
fusion at 1 year post-surgery. The composition is also eVec-
tive in containing the graft within the surgical site, resisting
irrigation. More clinical studies using recommended
designs are needed to further evaluate newer generation
DBMs and more discriminating techniques, such as CT
scans, should be considered to better assess the progression
of fusion.
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